You are here: Industry Insights > blood cancer

News List

NICE recommend venetoclax and azacytidine for patients with aggressive blood cancer PharmaTimes
December 17, 2021
Venetoclax is an oral once-daily treatment, which blocks the action of the B-cell lymphoma-2 protein, the presence of which helps cancer cells survive.
Kite and Appia Bio to develop allogeneic cell therapies for blood cancer pharmaceutical-technology
August 09, 2021
Gilead unit Kite and Appia Bio have signed a partnership and licence agreement to research and develop off-the-shelf allogeneic cell treatments from hematopoietic stem cells (HSCs) for haematological cancers.
Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights, July 2021 europeanpharmaceuticalreview
July 14, 2021
The Pharmacovigilance Risk Assessment Committee (PRAC) provided safety warnings on COVID-19 vaccines, and found no evidence linking Zynteglo to blood cancer.
Jazz Pharma’s blood cancer therapy Rylaze wins US approval pharmatimes
July 02, 2021
The US Food and Drug Administration has approved Dublin-based Jazz Pharmaceutical’s Rylaze for the treatment of two blood cancers – acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL).
Cancer Research UK partners with Aleta Biotherapeutics on blood cancer therapy pharmatimes
June 24, 2021
Cancer Research UK (CRUK) and biotech company Aleta Biotherapeutics have entered into a collaboration on the early phase clinical development of Aleta’s blood cancer therapy candidate ALETA-001.
PharmaEssentia resubmits BLA for polycythemia vera therapeutic pharmaceutical-technology
May 18, 2021
US subsidiary of Taiwan, China-based PharmaEssentia has resubmitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) to obtain approval for ropeginterferon alfa-2b-njft for polycythemia vera (PV) treatment.
Using personalized medicine to avoid resistance to leukemia treatment worldpharmanews
May 11, 2021
T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. It is relatively rare but still draws a lot of attention as it mostly develops in children under the age of 20.
Researchers identify new genetic target for acute myeloid leukaemia pharmatimes
May 07, 2021
Researchers from the Wellcome Sanger Institute have identified a new genetic target, which is linked with poor prognosis, for the potential treatment of acute myeloid leukaemia (AML) – a type of blood cancer.
NICE rejects Kyowa Kirin’s rare blood cancer drug Poteligeo for NHS use pharmaceutical-technology
March 05, 2021
The UK’s drug pricing regulator the National Institute for Health and Care Excellence (NICE) has decided not to recommend Kyowa Kirin’s Poteligeo (mogamulizumab) for routine use in the National Health Service (NHS) in England and Wales.
Roche reveals new bispecific antibody data in blood cancers pharmatimes
December 10, 2020
Swiss pharma company Roche has revealed positive early data for its investigational bispecific antibodies mosunetuzumab, glofitamab and cevostamab in a range of blood cancer types.

Previous page 1 2 3 Next page